Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Investors with a lot of money to spend have taken a bullish stance on Pfizer (NYSE:PFE).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PFE, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 11 uncommon options trades for Pfizer.
This isn't normal.
The overall sentiment of these big-money traders is split between 54% bullish and 18%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $173,564, and 7 are calls, for a total amount of $418,662.
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $35.0 for Pfizer, spanning the last three months.
In terms of liquidity and interest, the mean open interest for Pfizer options trades today is 14263.62 with a total volume of 5,044.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Pfizer's big money trades within a strike price range of $20.0 to $35.0 over the last 30 days.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
PFE | CALL | SWEEP | BEARISH | 01/16/26 | $5.8 | $5.6 | $5.65 | $25.00 | $112.3K | 22.6K | 202 |
PFE | CALL | TRADE | BULLISH | 12/19/25 | $9.5 | $9.4 | $9.5 | $20.00 | $95.0K | 1.8K | 100 |
PFE | CALL | TRADE | BULLISH | 01/16/26 | $10.2 | $8.15 | $9.6 | $20.00 | $64.3K | 6.3K | 67 |
PFE | CALL | TRADE | NEUTRAL | 01/16/26 | $5.85 | $5.55 | $5.72 | $25.00 | $57.2K | 22.6K | 302 |
PFE | PUT | TRADE | NEUTRAL | 11/15/24 | $0.97 | $0.95 | $0.96 | $28.00 | $48.0K | 6.8K | 2.0K |
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $37.2.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with Benzinga Pro for real-time alerts.
Posted In: PFE